- $214.09m
- $154.65m
- $26.39m
- 47
- 36
- 10
- 21
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 0.74 | ||
| Price to Tang. Book | 3.26 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 8.11 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -24% | ||
| Return on Equity | -20.6% | ||
| Operating Margin | -282.3% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 23.27 | 34.75 | 59.08 | 34.16 | 26.39 | 22.89 | 32.13 | 7.58% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform, Biological Intelligence, powers the immune systems of its engineered transgenic animals to create optimized antibody candidates for human therapeutics. Its proprietary transgenic animals, including OmniRat, OmniChicken and OmniMouse are genetically modified to generate antibodies with human sequences to streamline the development of human therapeutic candidates. OmniFlic and OmniClic are fixed or common light-chain rats and chickens, designed to facilitate the discovery of bispecific antibodies. OmniTaur provides cow-inspired antibodies with unique structural characteristics for challenging targets.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- October 31st, 2022
- Public Since
- October 9th, 2020
- No. of Shareholders
- 1,931
- No. of Employees
- 114
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
NASDAQ Global Market- Shares in Issue
- 122,335,336
- Address
- 5980 Horton Street, Suite 600, EMERYVILLE, 94608
- Web
- https://www.omniab.com/
- Phone
- +1 5102507800
- Auditors
- Ernst & Young LLP
Upcoming Events for OABI
Q1 2025 OmniAb Inc Earnings Call
OmniAb Inc at HC Wainwright Royalty Company Conference (Virtual)
OmniAb Inc at HC Wainwright BioConnect Investor Conference
OmniAb Inc at RBC Capital Markets Global Healthcare Conference
OmniAb Inc at Benchmark Healthcare House Call Conference (Virtual)
OmniAb Inc at Jefferies Global Healthcare Conference
OmniAb Inc Annual Shareholders Meeting
Q2 2025 OmniAb Inc Earnings Release
Similar to OABI
89bio
NASDAQ Global Market
Abivax SA
NASDAQ Global Market
ABPRO Holdings
NASDAQ Global Market
AC Immune SA
NASDAQ Global Market
Acrivon Therapeutics
NASDAQ Global Market
FAQ
What is the OmniAB share price?
As of Today at 22:27 UTC, shares in OmniAB are trading at $1.75. This share price information is delayed by 15 minutes.
How has the OmniAB share price performed this year?
Shares in OmniAB last closed at $1.75 and the price had moved by -61.96% over the past 365 days. In terms of relative price strength the OmniAB share price has underperformed the S&P500 Index by -65.7% over the past year.
What are the analyst and broker recommendations for OmniAB?
The overall consensus recommendation for OmniAB is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the OmniAB dividend yield?
OmniAB does not currently pay a dividend.
Does OmniAB pay a dividend?
OmniAB does not currently pay a dividend.
When does OmniAB next pay dividends?
OmniAB does not currently pay a dividend.
How do I buy OmniAB shares?
To buy shares in OmniAB you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of OmniAB?
As of the previous close price of $1.75, shares in OmniAB had a market capitalisation of $214.09m.
Where are OmniAB shares listed?
Here are the trading details for OmniAB:
- Country of listing: United States
- Exchange: NMQ
- Ticker Symbol: OABI
What kind of share is OmniAB?
Based on an overall assessment of its quality, value and momentum OmniAB is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a OmniAB share price forecast for 2025?
The analyst consensus target price for shares in OmniAB is $7.83. That is 347.43% above the last closing price of $1.75.
Analysts covering OmniAB currently have a consensus Earnings Per Share (EPS) forecast of -$0.60 for the next financial year.
Find out moreWhat is the trend in the OmniAB share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like OmniAB. Over the past six months, its share price has underperformed the S&P500 Index by -57.94%.
As of the last closing price of $1.75, shares in OmniAB were trading -51.73% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the OmniAB PE Ratio?
The OmniAB PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $1.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of OmniAB?
We do not have data on OmniAB's directors